ArticleACS omega2022
Preparation and Properties of Spherical CL-20 Composites.
Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Micrometer-sized spherical composites based on 2,4,6,8,10,12-hexanitrohexaazaisowurtzitane (CL-20) with fluororubber (F2604), dioctyl sebacate (DOS), and polyvinyl butyral (PVB) were prepared by an electrospray method. After preparation, the morphology, chemical bonds, thermal decomposition properties, mechanical sensitivity, and explosion performance were characterized. The main explosive CL-20 transformed from ε-CL-20 to β-CL-20 after electrospray preparation. With an insensitive additive mass ratio of 5 wt %, the CL-20/F2604 composite had the highest maximum peak exothermic temperature and the lowest mechanical sensitivity. The explosion pressures of the composites with the same mass ratio of additives decreased in the order CL-20/F2604 > CL-20/PVB > CL-20/DOS and were lower than that of raw CL-20.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.